http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 28 Jul 2026 08:03:31 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/FDA+clears+Corbus+Pharma+to+begin+CRB-701+cancer+study/26822819.html <p>Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) announced that the U.S. Food and Drug Administration has cleared the start of its registrational study, known as TEMPO-1, of CRB-701 in second-line oropharyngeal squamous cell carcinoma (OPSCC). The company expects to begin enrollment in September 2026.</p><p>TEMPO-1 is a randomized controlled study enrolling 250 patients, designed to evaluate the efficacy and safety of CRB-701 compared with investigator's choice of capecitabine, cetuximab, or docetaxel. The study's primary endpoint is objective response rate, intended to support a potential accelerated approval, while overall survival is intended to support potential conversion to full approval.</p><p>The FDA's clearance was supported http://www.streetinsider.com/Corporate+News/FDA+clears+Corbus+Pharma+to+begin+CRB-701+cancer+study/26822819.html Tue, 28 Jul 2026 08:03:31 -0400 CRBP http://www.streetinsider.com/FDA/FDA+clears+Corbus+Pharma+to+begin+CRB-701+cancer+study/26822819.html <p>Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) announced that the U.S. Food and Drug Administration has cleared the start of its registrational study, known as TEMPO-1, of CRB-701 in second-line oropharyngeal squamous cell carcinoma (OPSCC). The company expects to begin enrollment in September 2026.</p><p>TEMPO-1 is a randomized controlled study enrolling 250 patients, designed to evaluate the efficacy and safety of CRB-701 compared with investigator's choice of capecitabine, cetuximab, or docetaxel. The study's primary endpoint is objective response rate, intended to support a potential accelerated approval, while overall survival is intended to support potential conversion to full approval.</p><p>The FDA's clearance was supported http://www.streetinsider.com/FDA/FDA+clears+Corbus+Pharma+to+begin+CRB-701+cancer+study/26822819.html Tue, 28 Jul 2026 08:03:31 -0400 CRBP http://www.streetinsider.com/Press+Releases/Corbus+Pharmaceuticals+Announces+FDA+Clearance+to+Initiate+TEMPO-1+Registrational+Study+of+CRB-701+in+Patients+with+2L+Oropharyngeal+Cancer/26822770.html <ul type="disc"><li><em>Company expects to initiate enrollment in TEMPO-1 in September 2026</em><br/></li><li style="margin-bottom:1pt;"><em>OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L setting in the U.S. with approximately 14,000 patients eligible annually for treatment </em><br/><br/></li></ul> <p align="justify">NORWOOD, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) a clinical-stage company focusing on developing new therapies in oncology and obesity, today announced that the U.S. Food and Drug Administration (FDA) has cleared the start of the Company’s registrational study (“TEMPO-1”) of CRB-701, a next-generation http://www.streetinsider.com/Press+Releases/Corbus+Pharmaceuticals+Announces+FDA+Clearance+to+Initiate+TEMPO-1+Registrational+Study+of+CRB-701+in+Patients+with+2L+Oropharyngeal+Cancer/26822770.html Tue, 28 Jul 2026 08:00:00 -0400 A.06822034 A.50216726 CRBP O.20026344 O.21612337 O.22488230 http://www.streetinsider.com/Press+Releases/Corbus+Pharmaceuticals+Announces+FDA+Clearance+to+Initiate+TEMPO-1+Registrational+Study+of+CRB-701+in+Patients+with+2L+Oropharyngeal+Cancer/26822770.html <ul type="disc"><li><em>Company expects to initiate enrollment in TEMPO-1 in September 2026</em><br/></li><li style="margin-bottom:1pt;"><em>OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L setting in the U.S. with approximately 14,000 patients eligible annually for treatment </em><br/><br/></li></ul> <p align="justify">NORWOOD, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) a clinical-stage company focusing on developing new therapies in oncology and obesity, today announced that the U.S. Food and Drug Administration (FDA) has cleared the start of the Company’s registrational study (“TEMPO-1”) of CRB-701, a next-generation http://www.streetinsider.com/Press+Releases/Corbus+Pharmaceuticals+Announces+FDA+Clearance+to+Initiate+TEMPO-1+Registrational+Study+of+CRB-701+in+Patients+with+2L+Oropharyngeal+Cancer/26822770.html Tue, 28 Jul 2026 08:00:00 -0400 A.06822034 A.50216726 CRBP O.20026344 O.21612337 O.22488230 http://www.streetinsider.com/Press+Releases/Corbus+Pharmaceuticals+Announces+FDA+Clearance+to+Initiate+TEMPO-1+Registrational+Study+of+CRB-701+in+Patients+with+2L+Oropharyngeal+Cancer/26822770.html <ul type="disc"><li><em>Company expects to initiate enrollment in TEMPO-1 in September 2026</em><br/></li><li style="margin-bottom:1pt;"><em>OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L setting in the U.S. with approximately 14,000 patients eligible annually for treatment </em><br/><br/></li></ul> <p align="justify">NORWOOD, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) a clinical-stage company focusing on developing new therapies in oncology and obesity, today announced that the U.S. Food and Drug Administration (FDA) has cleared the start of the Company’s registrational study (“TEMPO-1”) of CRB-701, a next-generation http://www.streetinsider.com/Press+Releases/Corbus+Pharmaceuticals+Announces+FDA+Clearance+to+Initiate+TEMPO-1+Registrational+Study+of+CRB-701+in+Patients+with+2L+Oropharyngeal+Cancer/26822770.html Tue, 28 Jul 2026 08:00:00 -0400 A.06822034 A.50216726 CRBP O.20026344 O.21612337 O.22488230 http://www.streetinsider.com/Press+Releases/Corbus+Pharmaceuticals+Announces+FDA+Clearance+to+Initiate+TEMPO-1+Registrational+Study+of+CRB-701+in+Patients+with+2L+Oropharyngeal+Cancer/26822770.html <ul type="disc"><li><em>Company expects to initiate enrollment in TEMPO-1 in September 2026</em><br/></li><li style="margin-bottom:1pt;"><em>OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L setting in the U.S. with approximately 14,000 patients eligible annually for treatment </em><br/><br/></li></ul> <p align="justify">NORWOOD, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) a clinical-stage company focusing on developing new therapies in oncology and obesity, today announced that the U.S. Food and Drug Administration (FDA) has cleared the start of the Company’s registrational study (“TEMPO-1”) of CRB-701, a next-generation http://www.streetinsider.com/Press+Releases/Corbus+Pharmaceuticals+Announces+FDA+Clearance+to+Initiate+TEMPO-1+Registrational+Study+of+CRB-701+in+Patients+with+2L+Oropharyngeal+Cancer/26822770.html Tue, 28 Jul 2026 08:00:00 -0400 A.06822034 A.50216726 CRBP O.20026344 O.21612337 O.22488230 http://www.streetinsider.com/Press+Releases/Corbus+Pharmaceuticals+Announces+FDA+Clearance+to+Initiate+TEMPO-1+Registrational+Study+of+CRB-701+in+Patients+with+2L+Oropharyngeal+Cancer/26822770.html <ul type="disc"><li><em>Company expects to initiate enrollment in TEMPO-1 in September 2026</em><br/></li><li style="margin-bottom:1pt;"><em>OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L setting in the U.S. with approximately 14,000 patients eligible annually for treatment </em><br/><br/></li></ul> <p align="justify">NORWOOD, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) a clinical-stage company focusing on developing new therapies in oncology and obesity, today announced that the U.S. Food and Drug Administration (FDA) has cleared the start of the Company’s registrational study (“TEMPO-1”) of CRB-701, a next-generation http://www.streetinsider.com/Press+Releases/Corbus+Pharmaceuticals+Announces+FDA+Clearance+to+Initiate+TEMPO-1+Registrational+Study+of+CRB-701+in+Patients+with+2L+Oropharyngeal+Cancer/26822770.html Tue, 28 Jul 2026 08:00:00 -0400 A.06822034 A.50216726 CRBP O.20026344 O.21612337 O.22488230 http://www.streetinsider.com/Press+Releases/Corbus+Pharmaceuticals+Announces+FDA+Clearance+to+Initiate+TEMPO-1+Registrational+Study+of+CRB-701+in+Patients+with+2L+Oropharyngeal+Cancer/26822770.html <ul type="disc"><li><em>Company expects to initiate enrollment in TEMPO-1 in September 2026</em><br/></li><li style="margin-bottom:1pt;"><em>OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L setting in the U.S. with approximately 14,000 patients eligible annually for treatment </em><br/><br/></li></ul> <p align="justify">NORWOOD, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) a clinical-stage company focusing on developing new therapies in oncology and obesity, today announced that the U.S. Food and Drug Administration (FDA) has cleared the start of the Company’s registrational study (“TEMPO-1”) of CRB-701, a next-generation http://www.streetinsider.com/Press+Releases/Corbus+Pharmaceuticals+Announces+FDA+Clearance+to+Initiate+TEMPO-1+Registrational+Study+of+CRB-701+in+Patients+with+2L+Oropharyngeal+Cancer/26822770.html Tue, 28 Jul 2026 08:00:00 -0400 A.06822034 A.50216726 CRBP O.20026344 O.21612337 O.22488230 http://www.streetinsider.com/Globe+Newswire/Corbus+Pharmaceuticals+Announces+FDA+Clearance+to+Initiate+TEMPO-1+Registrational+Study+of+CRB-701+in+Patients+with+2L+Oropharyngeal+Cancer/26822770.html <ul type="disc"><li><em>Company expects to initiate enrollment in TEMPO-1 in September 2026</em><br/></li><li style="margin-bottom:1pt;"><em>OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L setting in the U.S. with approximately 14,000 patients eligible annually for treatment </em><br/><br/></li></ul> <p align="justify">NORWOOD, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) a clinical-stage company focusing on developing new therapies in oncology and obesity, today announced that the U.S. Food and Drug Administration (FDA) has cleared the start of the Company’s registrational study (“TEMPO-1”) of CRB-701, a next-generation http://www.streetinsider.com/Globe+Newswire/Corbus+Pharmaceuticals+Announces+FDA+Clearance+to+Initiate+TEMPO-1+Registrational+Study+of+CRB-701+in+Patients+with+2L+Oropharyngeal+Cancer/26822770.html Tue, 28 Jul 2026 08:00:00 -0400 A.06822034 A.50216726 CRBP O.20026344 O.21612337 O.22488230 http://www.streetinsider.com/Globe+Newswire/Corbus+Pharmaceuticals+Announces+FDA+Clearance+to+Initiate+TEMPO-1+Registrational+Study+of+CRB-701+in+Patients+with+2L+Oropharyngeal+Cancer/26822770.html <ul type="disc"><li><em>Company expects to initiate enrollment in TEMPO-1 in September 2026</em><br/></li><li style="margin-bottom:1pt;"><em>OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L setting in the U.S. with approximately 14,000 patients eligible annually for treatment </em><br/><br/></li></ul> <p align="justify">NORWOOD, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) a clinical-stage company focusing on developing new therapies in oncology and obesity, today announced that the U.S. Food and Drug Administration (FDA) has cleared the start of the Company’s registrational study (“TEMPO-1”) of CRB-701, a next-generation http://www.streetinsider.com/Globe+Newswire/Corbus+Pharmaceuticals+Announces+FDA+Clearance+to+Initiate+TEMPO-1+Registrational+Study+of+CRB-701+in+Patients+with+2L+Oropharyngeal+Cancer/26822770.html Tue, 28 Jul 2026 08:00:00 -0400 A.06822034 A.50216726 CRBP O.20026344 O.21612337 O.22488230 http://www.streetinsider.com/Globe+Newswire/Corbus+Pharmaceuticals+Announces+FDA+Clearance+to+Initiate+TEMPO-1+Registrational+Study+of+CRB-701+in+Patients+with+2L+Oropharyngeal+Cancer/26822770.html <ul type="disc"><li><em>Company expects to initiate enrollment in TEMPO-1 in September 2026</em><br/></li><li style="margin-bottom:1pt;"><em>OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L setting in the U.S. with approximately 14,000 patients eligible annually for treatment </em><br/><br/></li></ul> <p align="justify">NORWOOD, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) a clinical-stage company focusing on developing new therapies in oncology and obesity, today announced that the U.S. Food and Drug Administration (FDA) has cleared the start of the Company’s registrational study (“TEMPO-1”) of CRB-701, a next-generation http://www.streetinsider.com/Globe+Newswire/Corbus+Pharmaceuticals+Announces+FDA+Clearance+to+Initiate+TEMPO-1+Registrational+Study+of+CRB-701+in+Patients+with+2L+Oropharyngeal+Cancer/26822770.html Tue, 28 Jul 2026 08:00:00 -0400 A.06822034 A.50216726 CRBP O.20026344 O.21612337 O.22488230 http://www.streetinsider.com/Globe+Newswire/Corbus+Pharmaceuticals+Announces+FDA+Clearance+to+Initiate+TEMPO-1+Registrational+Study+of+CRB-701+in+Patients+with+2L+Oropharyngeal+Cancer/26822770.html <ul type="disc"><li><em>Company expects to initiate enrollment in TEMPO-1 in September 2026</em><br/></li><li style="margin-bottom:1pt;"><em>OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L setting in the U.S. with approximately 14,000 patients eligible annually for treatment </em><br/><br/></li></ul> <p align="justify">NORWOOD, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) a clinical-stage company focusing on developing new therapies in oncology and obesity, today announced that the U.S. Food and Drug Administration (FDA) has cleared the start of the Company’s registrational study (“TEMPO-1”) of CRB-701, a next-generation http://www.streetinsider.com/Globe+Newswire/Corbus+Pharmaceuticals+Announces+FDA+Clearance+to+Initiate+TEMPO-1+Registrational+Study+of+CRB-701+in+Patients+with+2L+Oropharyngeal+Cancer/26822770.html Tue, 28 Jul 2026 08:00:00 -0400 A.06822034 A.50216726 CRBP O.20026344 O.21612337 O.22488230 http://www.streetinsider.com/Globe+Newswire/Corbus+Pharmaceuticals+Announces+FDA+Clearance+to+Initiate+TEMPO-1+Registrational+Study+of+CRB-701+in+Patients+with+2L+Oropharyngeal+Cancer/26822770.html <ul type="disc"><li><em>Company expects to initiate enrollment in TEMPO-1 in September 2026</em><br/></li><li style="margin-bottom:1pt;"><em>OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L setting in the U.S. with approximately 14,000 patients eligible annually for treatment </em><br/><br/></li></ul> <p align="justify">NORWOOD, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) a clinical-stage company focusing on developing new therapies in oncology and obesity, today announced that the U.S. Food and Drug Administration (FDA) has cleared the start of the Company’s registrational study (“TEMPO-1”) of CRB-701, a next-generation http://www.streetinsider.com/Globe+Newswire/Corbus+Pharmaceuticals+Announces+FDA+Clearance+to+Initiate+TEMPO-1+Registrational+Study+of+CRB-701+in+Patients+with+2L+Oropharyngeal+Cancer/26822770.html Tue, 28 Jul 2026 08:00:00 -0400 A.06822034 A.50216726 CRBP O.20026344 O.21612337 O.22488230 http://www.streetinsider.com/Globe+Newswire/Corbus+Pharmaceuticals+Announces+FDA+Clearance+to+Initiate+TEMPO-1+Registrational+Study+of+CRB-701+in+Patients+with+2L+Oropharyngeal+Cancer/26822770.html <ul type="disc"><li><em>Company expects to initiate enrollment in TEMPO-1 in September 2026</em><br/></li><li style="margin-bottom:1pt;"><em>OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L setting in the U.S. with approximately 14,000 patients eligible annually for treatment </em><br/><br/></li></ul> <p align="justify">NORWOOD, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) a clinical-stage company focusing on developing new therapies in oncology and obesity, today announced that the U.S. Food and Drug Administration (FDA) has cleared the start of the Company’s registrational study (“TEMPO-1”) of CRB-701, a next-generation http://www.streetinsider.com/Globe+Newswire/Corbus+Pharmaceuticals+Announces+FDA+Clearance+to+Initiate+TEMPO-1+Registrational+Study+of+CRB-701+in+Patients+with+2L+Oropharyngeal+Cancer/26822770.html Tue, 28 Jul 2026 08:00:00 -0400 A.06822034 A.50216726 CRBP O.20026344 O.21612337 O.22488230 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Corbus+Pharmaceuticals+++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26820020.html si-local-file:///var/storage/secattach/20260727/26820020.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Corbus+Pharmaceuticals+++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26820020.html Mon, 27 Jul 2026 16:27:00 -0400 CRBP O.22488230 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Corbus+Pharmaceuticals+++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26820020.html si-local-file:///var/storage/secattach/20260727/26820020.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Corbus+Pharmaceuticals+++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26820020.html Mon, 27 Jul 2026 16:27:00 -0400 CRBP O.22488230 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Corbus+Pharmaceuticals+++++++++++++++++Filed+by%3A+Smethurst+Dominic/26819609.html si-local-file:///var/storage/secattach/20260727/26819609.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Corbus+Pharmaceuticals+++++++++++++++++Filed+by%3A+Smethurst+Dominic/26819609.html Mon, 27 Jul 2026 16:07:00 -0400 CRBP O.22488230 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Corbus+Pharmaceuticals+++++++++++++++++Filed+by%3A+Smethurst+Dominic/26819609.html si-local-file:///var/storage/secattach/20260727/26819609.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Corbus+Pharmaceuticals+++++++++++++++++Filed+by%3A+Smethurst+Dominic/26819609.html Mon, 27 Jul 2026 16:07:00 -0400 CRBP O.22488230 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Corbus+Pharmaceuticals++++For%3A+Jul+02/26733109.html si-local-file:///var/storage/secattach/20260706/26733109.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Corbus+Pharmaceuticals++++For%3A+Jul+02/26733109.html Mon, 06 Jul 2026 08:16:00 -0400 CRBP O.22488230 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Corbus+Pharmaceuticals++++For%3A+Jul+02/26733109.html si-local-file:///var/storage/secattach/20260706/26733109.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Corbus+Pharmaceuticals++++For%3A+Jul+02/26733109.html Mon, 06 Jul 2026 08:16:00 -0400 CRBP O.22488230 http://www.streetinsider.com/Management+Changes/Corbus+Pharmaceuticals+names+new+chief+medical+officer/26733015.html <p>Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) has appointed Leonardo Viana Nicacio, M.D., as Chief Medical Officer, according to a company statement.</p> <p>Dr. Nicacio brings more than 20 years of pharmaceutical industry experience, most recently serving as Chief Medical Officer at Protara Therapeutics. Before that, he was Senior Vice President, Head of Clinical Development and Global Medical Affairs at Stemline Therapeutics, a subsidiary of the Menarini Group.</p> <p>From 2017 to 2023, Dr. Nicacio held roles of increasing responsibility at Seagen, which was acquired by Pfizer in December 2023, most recently as Vice President of Clinical Development. In that role, he worked on programs http://www.streetinsider.com/Management+Changes/Corbus+Pharmaceuticals+names+new+chief+medical+officer/26733015.html Mon, 06 Jul 2026 08:01:36 -0400 A.02858308 A.03873598 A.06822034 A.20313903 A.50110121 A.50216726 CRBP O.00047492 O.00644488 O.01770903 O.02319593 O.20026344 O.21612337 O.22488230 O.45219732 S1GE34 http://www.streetinsider.com/Management+Changes/Corbus+Pharmaceuticals+names+new+chief+medical+officer/26733015.html <p>Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) has appointed Leonardo Viana Nicacio, M.D., as Chief Medical Officer, according to a company statement.</p> <p>Dr. Nicacio brings more than 20 years of pharmaceutical industry experience, most recently serving as Chief Medical Officer at Protara Therapeutics. Before that, he was Senior Vice President, Head of Clinical Development and Global Medical Affairs at Stemline Therapeutics, a subsidiary of the Menarini Group.</p> <p>From 2017 to 2023, Dr. Nicacio held roles of increasing responsibility at Seagen, which was acquired by Pfizer in December 2023, most recently as Vice President of Clinical Development. In that role, he worked on programs http://www.streetinsider.com/Management+Changes/Corbus+Pharmaceuticals+names+new+chief+medical+officer/26733015.html Mon, 06 Jul 2026 08:01:36 -0400 A.02858308 A.03873598 A.06822034 A.20313903 A.50110121 A.50216726 CRBP O.00047492 O.00644488 O.01770903 O.02319593 O.20026344 O.21612337 O.22488230 O.45219732 S1GE34 http://www.streetinsider.com/Management+Changes/Corbus+Pharmaceuticals+names+new+chief+medical+officer/26733015.html <p>Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) has appointed Leonardo Viana Nicacio, M.D., as Chief Medical Officer, according to a company statement.</p> <p>Dr. Nicacio brings more than 20 years of pharmaceutical industry experience, most recently serving as Chief Medical Officer at Protara Therapeutics. Before that, he was Senior Vice President, Head of Clinical Development and Global Medical Affairs at Stemline Therapeutics, a subsidiary of the Menarini Group.</p> <p>From 2017 to 2023, Dr. Nicacio held roles of increasing responsibility at Seagen, which was acquired by Pfizer in December 2023, most recently as Vice President of Clinical Development. In that role, he worked on programs http://www.streetinsider.com/Management+Changes/Corbus+Pharmaceuticals+names+new+chief+medical+officer/26733015.html Mon, 06 Jul 2026 08:01:36 -0400 A.02858308 A.03873598 A.06822034 A.20313903 A.50110121 A.50216726 CRBP O.00047492 O.00644488 O.01770903 O.02319593 O.20026344 O.21612337 O.22488230 O.45219732 S1GE34 http://www.streetinsider.com/Management+Changes/Corbus+Pharmaceuticals+names+new+chief+medical+officer/26733015.html <p>Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) has appointed Leonardo Viana Nicacio, M.D., as Chief Medical Officer, according to a company statement.</p> <p>Dr. Nicacio brings more than 20 years of pharmaceutical industry experience, most recently serving as Chief Medical Officer at Protara Therapeutics. Before that, he was Senior Vice President, Head of Clinical Development and Global Medical Affairs at Stemline Therapeutics, a subsidiary of the Menarini Group.</p> <p>From 2017 to 2023, Dr. Nicacio held roles of increasing responsibility at Seagen, which was acquired by Pfizer in December 2023, most recently as Vice President of Clinical Development. In that role, he worked on programs http://www.streetinsider.com/Management+Changes/Corbus+Pharmaceuticals+names+new+chief+medical+officer/26733015.html Mon, 06 Jul 2026 08:01:36 -0400 A.02858308 A.03873598 A.06822034 A.20313903 A.50110121 A.50216726 CRBP O.00047492 O.00644488 O.01770903 O.02319593 O.20026344 O.21612337 O.22488230 O.45219732 S1GE34 http://www.streetinsider.com/Management+Changes/Corbus+Pharmaceuticals+names+new+chief+medical+officer/26733015.html <p>Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) has appointed Leonardo Viana Nicacio, M.D., as Chief Medical Officer, according to a company statement.</p> <p>Dr. Nicacio brings more than 20 years of pharmaceutical industry experience, most recently serving as Chief Medical Officer at Protara Therapeutics. Before that, he was Senior Vice President, Head of Clinical Development and Global Medical Affairs at Stemline Therapeutics, a subsidiary of the Menarini Group.</p> <p>From 2017 to 2023, Dr. Nicacio held roles of increasing responsibility at Seagen, which was acquired by Pfizer in December 2023, most recently as Vice President of Clinical Development. In that role, he worked on programs http://www.streetinsider.com/Management+Changes/Corbus+Pharmaceuticals+names+new+chief+medical+officer/26733015.html Mon, 06 Jul 2026 08:01:36 -0400 A.02858308 A.03873598 A.06822034 A.20313903 A.50110121 A.50216726 CRBP O.00047492 O.00644488 O.01770903 O.02319593 O.20026344 O.21612337 O.22488230 O.45219732 S1GE34